Cargando…
Impact of different approaches to calculation of treatment activities on achieved doses in radioiodine therapy of benign thyroid diseases
PURPOSE: Radioiodine has been used for the treatment of benign thyroid diseases for over 70 years. However, internationally, there is no common standard for pretherapeutic dosimetry to optimally define the individual therapy activity. Here, we analyze how absorbed tissue doses are influenced by diff...
Autores principales: | Hammes, Jochen, van Heek, Lutz, Hohberg, Melanie, Reifegerst, Manuel, Stockter, Simone, Dietlein, Markus, Wild, Markus, Drzezga, Alexander, Schmidt, Matthias, Kobe, Carsten |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer International Publishing
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6289932/ https://www.ncbi.nlm.nih.gov/pubmed/30539323 http://dx.doi.org/10.1186/s40658-018-0231-x |
Ejemplares similares
-
Uptake in non-affected bone tissue does not differ between [(18)F]-DCFPyL and [(68)Ga]-HBED-CC PSMA PET/CT
por: Hammes, Jochen, et al.
Publicado: (2018) -
Biodistribution and radiation dosimetry of [(18)F]-JK-PSMA-7 as a novel prostate-specific membrane antigen-specific ligand for PET/CT imaging of prostate cancer
por: Hohberg, Melanie, et al.
Publicado: (2019) -
[(18)F]-JK-PSMA-7 PET/CT Under Androgen Deprivation Therapy in Advanced Prostate Cancer
por: Dietlein, Felix, et al.
Publicado: (2020) -
Comparison of [(18)F]DCFPyL and [(68)Ga]Ga-PSMA-HBED-CC for PSMA-PET Imaging in Patients with Relapsed Prostate Cancer
por: Dietlein, Markus, et al.
Publicado: (2015) -
Translational Development of a Zr-89-Labeled Inhibitor of Prostate-specific Membrane Antigen for PET Imaging in Prostate Cancer
por: Vázquez, Sergio Muñoz, et al.
Publicado: (2021)